semaj83/ctmatch_classification huggingface dataset:
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Known or Suspected Focal Liver Lesions Patients between 18 and 75 years of age inclusive Patients (men or women) with at least one focal liver lesion, either identified or suspected by ultrasound (US), Computed Tomography (CT)/spiral-CT, conventional angiography, CT-angiography (CTA), CT-arterioportography (CTAP) or unenhanced / contrast-enhanced MRI* within 2 months before entering the study For reference, the following pathologies will meet the definition of 'focal liver lesions' Hepatocellular carcinoma Cholangiole carcinoma Metastasis Focal lymphoma Adenoma Focal nodular hyperplasia Hemangioma  Patients who have previously entered this study Patients who have received any contrast material within 24 hours before injection with study drug, or who are scheduled to receive any contrast material within 24 hours after injection Patients who are, or suspected to be, nursing Patients who require emergency treatment Patients with severely impaired hepatic or renal functions (e.g. serum glutamic-pyruvic transaminase (SGPT) twice the upper limit of reference range, acute renal failure) Patients who are clinically unstable and whose clinical course during the observation period is unpredictable (e.g. due to previous surgery, acute myocardial infarction) Patients with any physical or mental status that interferes with the signing of informed consent Patients with known anaphylactoid or anaphylactic reaction to any contrast media or hypersensitivity to any allergen including drugs Patients with a contraindication for MRI Patients who are scheduled for liver biopsy/surgery or other surgeries within 24 hours after injection with contrast media, or who would have a biopsy within 24 hours before planned injection with contrast media
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Bacterial Vaginosis All women of between 18-50 years of age Confirmed current diagnosis of BV using Amsel's criteria Women with at least total 2 confirmed episodes of BV including most recent episode (by Amsel's criteria) within a six month period or at least total three or more in the past twelve months  Patient who received antibiotic therapy within the past two weeks Patients who had co-existing gonorrhea or Chlamydia infection Any contraindications or sensitivity to taking the vaginal gel Allergy to metronidazole Alcoholics or those unable to abstain from alcohol consumption Pregnancy
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Travelers' Diarrhea Male or female between 18 and 45 years of age, inclusive General good health, without significant medical illness, abnormal physical examination findings or clinical laboratory abnormalities as determined by principal investigator (PI) or PI in consultation with the medical monitor and Sponsor Demonstrate comprehension of the protocol procedures and knowledge of ETEC illness by passing a written examination (pass grade ≥ 70%) Willing to participate after informed consent obtained Available for entire inpatient portion of study and all outpatient study visits Negative serum pregnancy test at screening (initial visit and day -7 to and a negative urine pregnancy test on the day of admission to the inpatient phase for female subjects of childbearing potential. Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Alternatively, abstinence alone is acceptable. Female subjects who are unable to bear children must provide supporting documentation (e.g., prior tubal ligation or hysterectomy)  Presence of a significant medical condition, (e.g., psychiatric conditions or gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis or gastroesophageal reflux disease, inflammatory bowel disease, alcohol or illicit drug abuse/dependency), or other laboratory abnormalities which in the opinion of the investigator precludes participation in the study Immunosuppressive illness or IgA deficiency (below the normal limits) Positive serology results for HIV, HBsAg, or HCV antibodies Significant abnormalities in screening laboratory hematology, serum chemistry, urinalysis, as determined by PI or PI in consultation with the medical monitor and Sponsor Allergy to fluoroquinolones, cotrimoxazole, or ampicillin/penicillin (excluded if allergic to two of three) Fewer than 3 stools per week or more than 3 stools per day as the usual frequency; loose or liquid stools other than on an occasional basis History of diarrhea in the 2 weeks prior to planned inpatient phase Regular use of laxatives or any agent that increases gastric pH (regular defined as at least weekly) Use of antibiotics during the 7 days before bacterial dosing or proton pump inhibitors, H2 blockers, or antacids within 48 hours of dosing Travel to countries where ETEC or cholera infection is endemic (most of the developing world) within two years prior to dosing
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 0.75-1.0,  Cholera Diarrhea Vibrio Infections Healthy male and female infants aged 9 months will be recruited from Vellore, India and Dhaka, Bangladesh All subjects must satisfy the following at study entry Male or female infants aged 9 months whose parents or primary caretaker have given the written informed consent prior to study entry Will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection) Healthy subjects as determined by Medical history Physical examination Clinical judgment of the investigator  Parents or primary caregiver are unwilling or unable to give written informed consent to participate in the study Ongoing serious chronic disease Immunocompromising condition or therapy Abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours Intake of any anti-diarrheal medicine in the past week Acute disease one week prior to enrollment, with or without fever. Temperature ≥38ºC (oral) or axillary temperature ≥ 37.5ºC warrants deferral of the vaccination pending recovery of the subject Receipt of antibiotics in the past 2 weeks Receipt of live or killed enteric vaccine in the last 4 weeks Diarrhea (3 or more loose stools within a 24-hour period) 6 weeks prior to enrollment One or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 7.0-60.0,  Exocrine Pancreatic Insufficiency Steatorrhea Malabsorption Syndromes Cystic Fibrosis Have a diagnosis of CF documented by sweat chloride results (>60 mmol/L) and require pancreatic enzyme replacement therapy (PERT) to control clinical symptoms of EPI (nausea, vomiting, bloating, diarrhea, and abdominal pain) with a history of excess fat in the feces Have documentation of an abnormal COA-fat and a fecal elastase result of <100 micrograms fecal elastase/gram stool Must be on a stable diet and dose of pancreatic enzyme supplementation that has provided satisfactory symptom control for at least the past 1 month  No extreme physical wasting with loss of weight and muscle mass No severe, acute, or chronic pulmonary disease unrelated to complications of CF No worsening of pulmonary disease in past 30 days No use of drugs known to affect blood uric acid concentrations (e.g., aspirin, diflunisal, allopurinol, probenecid, thiazide diuretics, phenylbutazone, sulfinpyrazone) No known congenital (present at birth) abnormalities of the gastrointestinal tract, heart, or liver No distal intestinal obstruction syndrome (DIOS)
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Cholera Vibrio Infections Diarrhea HIV-seropositive, non-pregnant adults, aged 18 years old who have been on standard highly active antiretroviral therapy (HAART) for at least 6 months prior to enrollment or who have never started HAART regimen will be recruited in the study All subjects must satisfy the following at study entry Male and female HIV seropositive adults aged 18 to 45 years old who have given the written informed consent Will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection) CD4 T-lymphocyte count >500/mm3 for at least 6 months prior to Subjects that have never started HAART regimen must satisfy the following additional at study entry Asymptomatic HIV infection as determined by: Medical history, Physical examination, Laboratory tests, Clinical judgment of the investigator Subjects that have been on standard highly active antiretroviral therapy (HAART) for at least 6 months prior to enrollment must satisfy the following additional at study entry History of CD4 nadir >150/mm3  The following should be checked at the time of study entry, if any of the following is present then the subject will be excluded from the study Overt signs of immunodeficiency e.g. oral thrush, rapid weight loss, recurrent pneumonia (i.e. Stage 3 or 4 of the WHO clinical staging system for HIV infection and disease in adults and adolescents Ongoing serious chronic illness (e.g. with signs of cardiac or renal failure) Abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours Presence of V. cholerae 01 or 0139, Shigella, or Cryptosporidium in stool at baseline Intake of any anti-diarrhoeal medicine in the past week Acute disease one week prior to enrollment, with or without fever. Temperature ≥38ºC (oral or otic) warrants deferral of the vaccination pending recovery of the subject Receipt of antibiotics in the past 2 weeks Receipt of live or killed enteric vaccine in the last 4 weeks Receipt of killed oral cholera vaccine in the past
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Bacterial Vaginosis women 18-40 yrs old abnormal vaginal discharge or malodor positive QuickVue test positive KOH whiff test Positive finding of clue cells greater than or equal to 20% on wet mount Able to give informed consent willing to abstain from alcohol during the 5 day therapy and 1 day following  immunocompromised women symptomatic VVC pregnancy or positive pregnancy test menstruating or breastfeeding women other oral or vaginal antifungal or antimicrobial drugs w/in past 2 wks women with MPC, PID
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 14.0-50.0,  Clotrimazole Ovulen Vulvovaginal Candidiasis Non-pregnant females aged at least 14 years in Germany or at least 16 years in Russia and not older than 50 years Subjects presenting a symptomatic vulvovaginal yeast infection confirmed by microscopic evaluation (wet mount preparation) Subjects must be cooperative, able to understand the requirements of the trial participation, and willing to participate in the trial. For adolescents the informed consent has to be provided to a legal representative in addition Subjects of childbearing potential must use an acceptable method of contraception. Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are considered acceptable methods of contraception Negative saline smear for Trichomonas vaginalis  Subjects with known hypersensitivity to imidazoles or triazoles and their analogues Subjects presenting a protozoan infection as confirmed by microscopic investigation Pregnant, breast feeding or lactating subjects Subjects with suspected bacterial vaginal infection Subjects with abdominal pain, fever, or foul smelling vaginal discharge Subjects who had a vaginal infection, or who had used an intravaginal or systemic antimycotic treatment within 60 days prior to visit 1 Subjects using or wishing to use intra-vaginal or systemic anti-infectives or systemic antifungal therapy during the trial Subjects wishing to use contraceptive foams, creams, jellies, sponges, therapeutic ointments, condoms, diaphragms, and OTC vaginal products during treatment and 3 days thereafter (i.e. until day 4) Subjects unable to refrain from the use of vaginal tampons during treatment and for 3 days thereafter (i.e. until day 4) Subjects unable to refrain from the use of feminine hygiene products (e.g. douches, feminine deodorant products) for 2 weeks (i.e. from visit 1 until visit 2)
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Aged Subject (male or female) is at least 65 years of age Subject has a Geriatric Nutritional Risk Index (GNRI)of 92 or over Subject has Body Mass Index (BMI) > 20.0 but <30.0 Subject is ambulatory Subject agrees to maintain current activity level  Subject has undergone major surgery, less than 4 weeks prior to enrollment in the study Subject has current active malignant disease, except basal or squamous cell skin carcinoma or carcinoma in situ of the uterine cervix Subject has stated immunodeficiency disorder Subject has stated history of diabetes Subject has stated presence of partial or full artificial limb Subject has stated kidney disease Subject has stated history of uncontrollable hypertension Subject had myocardial infarction within the last 3 months Subject had recent antibiotic use (within 1 week prior to screening) Subject has a history of allergy to any of the ingredients in the study products
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Healthy Males Only healthy male volunteers in the 18-40 age range will be included At the selection visit allowed normal range for vital signs will be: Blood pressure (with the subject sitting down) 90-130mm Hg systolic and 60-90 The volunteers' health condition will be determined from their complete clinical history by doctors at the clinical research site and lab test results by certified clinical laboratories mm Hg diastolic, heart rate 55-100 bpm , respiratory rate 14-20 respirations per minute  Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at Screening Treatment with a PDE-5 inhibitor within the 4 days preceding the first dose of study medication History of hypersensitivity to sildenafil citrate or any components of its formulations
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy Volunteers Healthy subjects Weight: BMI from 17.5 to 30.5  Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) A positive urine drug screen
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy Volunteers Healthy male and/or female subjects (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests) Body Mass Index (BMI) of 18 to 26 kg/m2; and a total body weight >50 kg (110 lbs)  Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) A positive urine drug screen
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Traveler's Diarrhea Male and female patients 18 years of age or older Female and male patients of child-bearing potential must agree to use an effective method of birth control (this method must be approved by the investigator and may total abstinence from sexual intercourse) during the treatment and follow-up study periods; female patients of child-bearing potential must have a negative pregnancy test in the 72 hours before randomization; female patients who abstain totally from sexual intercourse are not required to take the pregnancy test Recent travel (i.e., must be within 30 days of randomization) from an industrialized country Experiencing signs or symptoms indicative of acute bacterial diarrhea (travelers' diarrhea), defined as at least three unformed, watery or soft, stools within the 24 hours preceding randomization and the duration of illness ≤ 72 hours before randomization, and able to provide an unformed stool sample during Screening (the latter can be the third unformed stool passed by the patient within the 24 hours preceding randomization); the bacterial cause of diarrhea will be confirmed by microbiology analysis of the stool sample Experiencing one or more signs or symptoms of enteric infection (moderate to severe gas/flatulence, nausea, vomiting, abdominal cramps or pain, rectal tenesmus, or defecation urgency) Capable of and willing to give informed consent  Fever (> 100.4ºF or 38ºC) or presence of signs and symptoms of systemic infection Note: antipyretic medication should not be administered in the 6 hours before this assessment Known or suspected infection with non-bacterial pathogen before randomization Presence of diarrhea for >72 hours duration Presence of grossly bloody stool Presence of moderate to severe dehydration (i.e., presence of orthostatic hypotension and/or dehydration requiring treatment with intravenous fluids) History of ulcerative colitis, diarrhea-predominant irritable bowel syndrome, Crohn's disease, celiac sprue (gluten-enteropathy), chronic pancreatitis, malabsorption, or any other gastrointestinal disease associated with diarrhea. Note: lactose intolerance treated with lactase supplements or a lactose-free diet are not excluded if these regimens are maintained during the study Receiving more than two doses of an antidiarrheal medication (e.g., antimotility, absorbent, adsorbent, antisecretory, or probiotics) within 24 hours before randomization Receiving one or more of the following antibiotics within 7 days before randomization, which are active against gram negative bacteria trimethoprim/sulfamethoxazole, fluoroquinolone, azithromycin or rifaximin Females pregnant or breast feeding or not using adequate birth control